TET2 and neoplasm: One study demonstrated that TET2 depletion could reduce Th1-type chemokines and PD-L1 expression by mediating the IFN-γ/JAK/STAT pathway, thereby decreasing tumor-infiltrating lymphocytes such as CD3+ and CD8+ T cell, and eventually it could compromise the efficacy of anti-PD-1/PD-L1 immunotherapy (Xu et al., 2019).